{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:01:59Z","timestamp":1791993719762,"version":"4.4.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["20 0156 F"],"award-info":[{"award-number":["20 0156 F"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["200170F"],"award-info":[{"award-number":["200170F"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114010","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T04:59:52Z","timestamp":1710133192000},"page":"114010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-4771","authenticated-orcid":false,"given":"Hildur","family":"Helgadottir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-9624","authenticated-orcid":false,"given":"Alexios","family":"Matikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Fernebro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Erik","family":"Fr\u00f6din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8343-6226","authenticated-orcid":false,"given":"Simon","family":"Ekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenny A.","family":"Rodriguez-Wallberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114010_bib1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","article-title":"Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma","volume":"72","author":"Kim","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.114010_bib2","article-title":"Targeting ALK rearrangements in NSCLC: current state of the art","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchio","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cam4.4968","article-title":"Association between mutational subgroups, Warburg-subtypes, and survival in patients with colorectal cancer","volume":"12","author":"Offermans","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.114010_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/life13051195","article-title":"The late effects of cancer treatment on female fertility and the current status of fertility preservation-a narrative review","volume":"13","author":"Rodriguez-Wallberg","year":"2023","journal-title":"Life"},{"issue":"4","key":"10.1016\/j.ejca.2024.114010_bib7","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum Reprod Open"},{"key":"10.1016\/j.ejca.2024.114010_bib8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib9","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Dagger) Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib10","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S1470-2045(23)00390-X","article-title":"Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement","volume":"24","author":"Cui","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib11","unstructured":"Global Cancer Observatory. International Agency for Research on Cancer (IARC) of the World Health Organization (WHO). https:\/\/gco.iarc.fr\/today\/en. Acceessed March 2024."},{"key":"10.1016\/j.ejca.2024.114010_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib13","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib14","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib17","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib18","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after introduction of adjuvant treatment in stage iii melanoma: a nationwide registry-based study","author":"Helgadottir","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.114010_bib20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102855","article-title":"Novel targets, novel treatments: the changing landscape of non-small cell lung cancer","volume":"15","author":"de Jong","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114010_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib24","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2024.114010_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2019.08.017","article-title":"Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study","volume":"155","author":"Johansen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1186\/s12885-020-07511-y","article-title":"A Swedish nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women","volume":"20","author":"Johansen","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejca.2024.114010_bib29","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib30","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib31","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2024.114010_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.114010_bib34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib35","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/AOG.0b013e3181b19154","article-title":"Increasing incidence of pregnancy-associated breast cancer in Sweden","volume":"114","author":"Andersson","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejca.2024.114010_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/jwh.2018.6962","article-title":"Pregnancy-associated cancer: A U.S. Population-Based Study","volume":"28","author":"Cottreau","year":"2019","journal-title":"J Women\u2019s Health (Larchmt)"},{"key":"10.1016\/j.ejca.2024.114010_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.03.042","article-title":"Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis","volume":"190","author":"Villacampa","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive her2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-22-2829","article-title":"Survival outcomes, digital TILs, and on-treatment pet\/ct during neoadjuvant therapy for her2-positive breast cancer: results from the randomized PREDIX HER2 Trial","volume":"29","author":"Matikas","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114010_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib43","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib44","unstructured":"Onkologirapport 2020. In: Samverkan RCi, editor.2022."},{"key":"10.1016\/j.ejca.2024.114010_bib45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.fertnstert.2008.07.1714","article-title":"Effects of cancer treatment on ovarian function","volume":"92","author":"Stroud","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejca.2024.114010_bib46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/0284186X.2015.1073349","article-title":"Assessment of testicular dose during preoperative radiotherapy for rectal cancer","volume":"55","author":"Buchli","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib47","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/SLA.0000000000002081","article-title":"Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study","volume":"267","author":"Buchli","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2024.114010_bib48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.114010_bib49","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib50","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib51","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib53","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114010_bib54","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","article-title":"Thyroid dysfunctions secondary to cancer immunotherapy","volume":"41","author":"Chalan","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejca.2024.114010_bib55","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/tcmj.tcmj_255_19","article-title":"Role of hypothyroidism and associated pathways in pregnancy and infertility: clinical insights","volume":"32","author":"Koyyada","year":"2020","journal-title":"Tzu Chi Med J"},{"key":"10.1016\/j.ejca.2024.114010_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejca.2024.114010_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2265.2006.02550.x","article-title":"Fertility outcomes in women with hypopituitarism","volume":"65","author":"Hall","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejca.2024.114010_bib58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1634\/theoncologist.2019-0837","article-title":"It Is Time to Talk About Fertility and Immunotherapy","volume":"25","author":"Duma","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114010_bib59","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fendo.2013.00174","article-title":"Thyroid function in male infertility","volume":"4","author":"Krajewska-Kulak","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejca.2024.114010_bib60","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.21176","article-title":"An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 Inhibitors","volume":"107","author":"Poulet","year":"2016","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.ejca.2024.114010_bib61","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaad.2016.04.031","article-title":"Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: fertility risk of food and drug administration-approved systemic therapies","volume":"75","author":"Walter","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2024.114010_bib62","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e15114","article-title":"Testicular histopathology after immunotherapy for metastatic melanoma","volume":"36","author":"Benz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib63","article-title":"Onset of azoospermia in man treated with ipilimumab\/nivolumab for BRAF negative metastatic melanoma","volume":"34","author":"Rabinowitz","year":"2021","journal-title":"Urol Case Rep"},{"key":"10.1016\/j.ejca.2024.114010_bib64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","article-title":"Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study","volume":"152","author":"Salzmann","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib65","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114010_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib67","doi-asserted-by":"crossref","first-page":"e550","DOI":"10.1016\/S1470-2045(21)00525-8","article-title":"Immunotherapy for cancer treatment during pregnancy","volume":"22","author":"Borgers","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib68","unstructured":"FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/ Accessed April 1st 2023."},{"key":"10.1016\/j.ejca.2024.114010_bib69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CMR.0000000000000657","article-title":"Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition","volume":"30","author":"Bucheit","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.114010_bib70","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib71","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2018.09.008","article-title":"Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy","volume":"104","author":"Menzer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib72","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.114010_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/CJI.0000000000000448","article-title":"Successful Pregnancy and Cancer Outcomes With Ipilimumab and Nivolumab for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature","volume":"46","author":"Zambrana","year":"2023","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2024.114010_bib74","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2308135","article-title":"Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab","volume":"389","author":"Baarslag","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib75","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2020.00232","article-title":"Fertility outcomes and sperm-DNA parameters in metastatic melanoma survivors receiving vemurafenib or dabrafenib therapy: case report","volume":"10","author":"Ghezzi","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib76","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/0284186X.2018.1449251","article-title":"Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma","volume":"57","author":"Cocorocchio","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.45.2870","article-title":"Treatment of metastatic malignant melanoma with vemurafenib during pregnancy","volume":"31","author":"Maleka","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib78","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/CMR.0000000000000600","article-title":"Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity","volume":"29","author":"Marce","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2024.114010_bib79","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.ejca.2024.114010_bib80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/molehr\/gal010","article-title":"Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis","volume":"12","author":"Hutt","year":"2006","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.ejca.2024.114010_bib81","doi-asserted-by":"crossref","DOI":"10.1530\/RAF-22-0020","article-title":"Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies","volume":"3","author":"Rosario","year":"2022","journal-title":"Reprod Fertil"},{"key":"10.1016\/j.ejca.2024.114010_bib82","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3892\/or.2020.7660","article-title":"Lapatinib\u2011induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro","volume":"44","author":"Liao","year":"2020","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2024.114010_bib83","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/sj.bjc.6602585","article-title":"Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients","volume":"92","author":"Nishio","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2021.09.001","article-title":"Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma","volume":"161","author":"Boudy","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib85","unstructured":"EMA. Summary of product characteristics (SmPC). https:\/\/www.ema.europa.eu\/en\/glossary\/summary-product-characteristics. Accessed May 17th 2023."},{"key":"10.1016\/j.ejca.2024.114010_bib86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jnci\/djy094","article-title":"Adjuvant Anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal her2-positive early breast cancer patients","volume":"111","author":"Lambertini","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2024.114010_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.6004\/jnccn.2022.7065","article-title":"Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer","volume":"21","author":"Lambertini","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2024.114010_bib88","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-021-06267-8","article-title":"Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)","volume":"189","author":"Ruddy","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.114010_bib89","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib90","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-012-2368-y","article-title":"Trastuzumab administration during pregnancy: a systematic review and meta-analysis","volume":"137","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.114010_bib91","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cncr.31784","article-title":"Pregnancies during and after trastuzumab and\/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials","volume":"125","author":"Lambertini","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123542","article-title":"Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism","volume":"10","author":"Witek","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2024.114010_bib93","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1002\/cncr.27450","article-title":"Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer","volume":"118","author":"Weickhardt","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114010_bib94","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.fertnstert.2016.08.011","article-title":"Ovarian stimulation in young adult cancer survivors on targeted cancer therapies","volume":"106","author":"Su","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejca.2024.114010_bib95","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2021.02.005","article-title":"First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report","volume":"16","author":"Scarfone","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib96","article-title":"Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report","volume":"3","author":"Weidenbaum","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ejca.2024.114010_bib97","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK Pathway in KRAS-Driven Tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2024.114010_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.991719","article-title":"Aberrant activation of KRAS in mouse theca-interstitial cells results in female infertility","volume":"13","author":"Sun","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.ejca.2024.114010_bib99","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2023.34.e53","article-title":"PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia","volume":"34","author":"Xue","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib100","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114010_bib101","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3892\/mco.2017.1237","article-title":"Ovarian function following targeted anti-angiogenic therapy with bevacizumab","volume":"6","author":"Imai","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib102","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ejca.2024.114010_bib103","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/humrep\/deaa128","article-title":"The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation","volume":"35","author":"Winship","year":"2020","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejca.2024.114010_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74087-9","article-title":"Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells","volume":"10","author":"Nakamura","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2024.114010_bib105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.2023.25463","article-title":"Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study","volume":"331","author":"Lambertini","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2024.114010_bib106","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1200\/JCO.20.02880","article-title":"Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data","volume":"39","author":"Turan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114010_bib107","doi-asserted-by":"crossref","first-page":"19225","DOI":"10.1002\/cam4.6527","article-title":"A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants","volume":"12","author":"Oktay","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.114010_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2007.07.029","article-title":"Fertility and adjuvant treatment in young women with breast cancer","volume":"16","author":"Partridge","year":"2007","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2024.114010_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15204923","article-title":"The Role of Cyclin-Dependent Kinases (CDK) 4\/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition","volume":"15","author":"Scavone","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2024.114010_bib110","unstructured":"Annals of Oncology (2022) 33 (suppl_3): S148-S164. 10.1016\/annonc\/annonc889."},{"key":"10.1016\/j.ejca.2024.114010_bib111","first-page":"6","article-title":"Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 \/ BIG 8-13)","author":"Partridge","year":"2022","journal-title":"San Antonio Breast Cancer Symp"},{"key":"10.1016\/j.ejca.2024.114010_bib112","doi-asserted-by":"crossref","first-page":"199","DOI":"10.32074\/1591-951X-787","article-title":"NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies","volume":"114","author":"Marchetti","year":"2022","journal-title":"Pathologica"},{"key":"10.1016\/j.ejca.2024.114010_bib113","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.21037\/tlcr-20-434","article-title":"How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?","volume":"9","author":"Ekman","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2024.114010_bib114","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ydbio.2003.12.001","article-title":"TrkB receptors are required for follicular growth and oocyte survival in the mammalian ovary","volume":"267","author":"Paredes","year":"2004","journal-title":"Dev Biol"},{"key":"10.1016\/j.ejca.2024.114010_bib115","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41467-022-28611-2","article-title":"TrkB agonist antibody ameliorates fertility deficits in aged and cyclophosphamide-induced premature ovarian failure model mice","volume":"13","author":"Qin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2024.114010_bib116","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/aogs.12934","article-title":"Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries - compilation of 20 years of multicenter experience","volume":"95","author":"Rodriguez-Wallberg","year":"2016","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ejca.2024.114010_bib117","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/03009734.2020.1737601","article-title":"Fertility preservation for young adults, adolescents, and children with cancer","volume":"125","author":"Rodriguez-Wallberg","year":"2020","journal-title":"Ups J Med Sci"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:23:35Z","timestamp":1778783015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":117,"alternative-id":["S0959804924001667"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114010"}}